Scott S. Liebman

Scott Liebman is Leader of the firm's Life Sciences Team and is based in the firm’s New York office. 

Areas of Practice

Scott focuses on complex FDA regulatory, compliance and legal matters affecting global pharmaceutical, biotechnology and medical device manufacturers. He counsels clients on federal and state requirements and develops legal and regulatory strategies to help commercialize their products.

Clients regularly turn to Scott and his team to support product launches; implement corporate integrity agreements; develop comprehensive training and monitor compliance programs; and handle anti-kickback, sampling and off-label investigations. Whether advising executives or training a national sales force, Scott knows that clear, thoughtful communication and practical advice are key to supporting his clients.

He has worked with businesses of all sizes, from small life sciences organizations launching their first product to Fortune 500 companies in the pharmaceutical and medical products/equipment industries. His clients operate worldwide and include Europe- and Asia-based life sciences companies.

Scott is passionate about understanding his clients’ challenges and is committed to learning their businesses inside and out to find solutions. He brings deep technical knowledge along with enthusiasm for his clients’ work to each client relationship.

Honors

Recommended Lawyer, Legal 500, 2024

Leading Life Sciences Lawyer - FDA Medical Device and FDA Pharmaceutical, LMG Life Sciences, 2021-2024

Health Care Trailblazer, The National Law Journal, 2020

Rising Star, the New York Law Journal, 2014

New Leaders of The Bar, New Jersey Law Journal, 2012

New York Metro Rising Star in Health Care Law, Thomson Reuters, 2014-2015

New Jersey Rising Star in Health Care Law, Thomson Reuters, 2013

Articles

FDA Law Blog Posts

• "LDT Final Rule Series: Part 2 – Response to the Rule," June 6, 2024
• "LDT Final Rule Series: Part 1 – Rule Overview," April 30, 2024

• "FDA Warning Letter Regulates 'Research Only' Labels," April 24, 2024
• "2024 Top-of-Mind Issues for Life Sciences Companies," January 25, 2024
• "OIG General Compliance Program Guidance November 2023," November 8, 2023
• "OIG Advisory Opinion Alert: Yet Another Favorable Decision for Medical Device Manufacturers," March 17, 2022

Media Mentions

Events